OTTAWA, ON, May 28, 2021 /CNW/ - Tetra Bio-Pharma
Inc. ("Tetra" or the "Company")
(TSX: TBP) (OTCQB: TBPMF) (FRA: JAM1), a leader in
cannabinoid-derived drug discovery and development, is pleased to
announce that all matters presented for approval at the Company's
annual general and special meeting (the "Meeting") of
shareholders of the Company held earlier today via live audio
webcast online were approved.
Election of Directors and Resolutions
All of the nominees listed in Tetra's management information
circular dated April 20, 2021, as
supplemented by a supplement to the management information circular
dated May 18, 2021 (the
"Circular"), namely Dr. Guy
Chamberland, Dale Weil,
Brent Norton, John Kim and Catherine
Auld, were elected as directors of the Company until the
next annual meeting of shareholders or until their successors are
elected or appointed. The initial management information circular
dated April 20, 2021 was listing
Messrs. Guy Chamberland,
Dale Norton and Carl Merton as well as Ms. Dale Weil as director nominees for the ensuing
year. Following such date, management continued its efforts to
identify suitable director candidates in order to increase its
board membership, resulting in the nominations of John Kim and Catherine
Auld as directors of the Corporation. In addition, on
May 18, 2021, Mr. Carl Merton announced that he would not be
seeking reelection as a director at this meeting of the
shareholders.
The proposal to appoint McGovern Hurley LLP as auditor of the
Company and to authorize the board of directors of the Company to
fix the remuneration to be paid to the auditor, as presented in the
Circular, was approved by a majority of shareholders at the
Meeting.
The ordinary resolution of the shareholders of the Company
approving the amended and restated omnibus equity incentive
compensation plan of the Company (the "Amended and Restated
Omnibus Plan") (having the effect of amending and restated the
current 2020 omnibus equity incentive plan of the Company) and
approving the unallocated awards thereunder, the whole for a period
of three (3) years and as more particularly described in the
Circular, was adopted by a majority of shareholders at the Meeting.
The Amended and Restated Omnibus Plan provides for a revised
amending provision and reflects other amendments of a
"housekeeping" nature in order to make the Company's equity
incentive compensation plan compliant with the TSX Company Manual.
In addition, the Amended and Restated Omnibus Plan provides for a
streamlined vesting and settlement mechanics for share units.
Please refer to the Company's report of voting results filed
under the Company's SEDAR profile at www.sedar.com on May 28, 2021 for further details on the above
matters.
About Tetra Bio-Pharma Inc.:
Tetra Bio-Pharma (TSX: TBP) (OTCQB: TBPMF) (FRA:JAM1) is a
leader in cannabinoid-derived drug discovery and development with a
FDA and a Health Canada cleared clinical program aimed at bringing
novel prescription drugs and treatments to patients and their
healthcare providers. Its evidence-based scientific approach has
enabled us to develop a pipeline of cannabinoid-based drug products
for a range of medical conditions, including pain, inflammation,
and oncology. With patients at the core of what we do, Tetra
Bio-Pharma is focused on providing rigorous scientific validation
and safety data required for inclusion into the existing biopharma
industry by regulators, physicians and insurance companies.
For more information visit: www.tetrabiopharma.com
SOURCE Tetra Bio-Pharma Inc.